EXPERIENCE OF PALIVIZUMAB IN PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRAL INFECTION IN PREMATURE CHILDREN WITH BRONCHOPULMONARY DYSPLASIA

The data on prophylaxis efficacy of the Palivizumab (synagis) against respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia are shown in the article. No side-effects, good tolerance and decrease of the frequency of bronchopulmonary dysplasia relapses and other viral diseases in whole in such children were registered.